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ABSTRACT Pseudomonas aeruginosa produces quorum sensing signal molecules that are potential
biomarkers for infection.
A prospective study of 60 cystic fibrosis patients with chronic P. aeruginosa, who required intravenous
antibiotics for pulmonary exacerbations, was undertaken. Clinical measurements and biological samples
were obtained at the start and end of the treatment period. Additional data were available for 29 of these
patients when they were clinically stable.
Cross-sectionally, quorum sensing signal molecules were detectable in the sputum, plasma and urine of
86%, 75% and 83% patients, respectively. They were positively correlated between the three biofluids.
Positive correlations were observed for most quorum sensing signal molecules in sputum, plasma and urine,
with quantitative measures of pulmonary P. aeruginosa load at the start of a pulmonary exacerbation.
Plasma concentrations of 2-nonyl-4-hydroxy-quinoline (NHQ) were significantly higher at the start of a
pulmonary exacerbation compared to clinical stability (p<0.01). Following the administration of systemic
antibiotics, plasma 2-heptyl-4-hydroxyquinoline (p=0.02) and NHQ concentrations (p<0.01) decreased
significantly.
In conclusion, quorum sensing signal molecules are detectable in cystic fibrosis patients with pulmonary
P. aeruginosa infection and are positively correlated with quantitative measures of P. aeruginosa. NHQ
correlates with clinical status and has potential as a novel biomarker for P. aeruginosa infection.
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Introduction
The majority of adults with cystic fibrosis (CF) are chronically infected with Pseudomonas aeruginosa,
which is associated with an accelerated decline in lung function [1], more frequent pulmonary
exacerbations and increased mortality [2]. The success of P. aeruginosa, as an opportunistic pathogen, is
partially attributed to the ability of whole bacterial populations of this bacterium to co-ordinate their
activity using cell-to-cell communication, mediated by quorum sensing signal molecules (QSSMs) [3].
Quorum sensing (QS) regulates over 10% of the P. aeruginosa genome including swarming motility,
biofilm maturation and antimicrobial resistance, as well as the production of virulence determinants such
as elastases, pyocyanin, cyanide and exotoxins [3]. QS dependent virulence factors are elevated in
bronchial secretions during episodes of pulmonary exacerbations in patients with CF [4]. These facts
provide indirect evidence to suggest that QSSMs may contribute to changes in clinical status.
QSSMs are detectable in sputum obtained from patients with CF [5, 6] and QSSM concentrations in
sputum are positively correlated with plasma levels [7]. This suggests that QSSMs have potential as
biomarkers for P. aeruginosa in both pulmonary and non-pulmonary biological samples and could
potentially be used to facilitate the diagnosis and response to treatment of this bacterium. The aim of this
study is to test the hypothesis that QSSMs in sputum, plasma and urine correlate with clinical status in the
adults with CF at the beginning and end of a pulmonary exacerbation, and also compared to clinical
stability. Our data show that systemic concentrations of several QSSMs correlate with changes in clinical
status, suggesting that they have potential as novel biomarkers for airway infection with P. aeruginosa.
Methods
Participants
Participants were recruited from two UK adult CF specialist centres, Nottingham University Hospitals
NHS Trust, Nottingham and Heart of England NHS Foundation Trust, Birmingham. Inclusion criteria
were a diagnosis of CF, age 16–60 years and chronic pulmonary infection with P. aeruginosa (defined as
>50% of cultures positive for P. aeruginosa in ≤12 months). Patients with chronic P. aeruginosa and
co-infections with other organisms were included in the study. The duration of chronic pulmonary
infection was defined as the earliest known date that P. aeruginosa was isolated that led to >50% positive
sputum cultures in the subsequent 12 months. Exclusion criteria were any previous isolation of
Burkholderia cepacia complex in sputum, previous lung transplant, pregnancy or advanced disease. The
local ethics committee approved the study (Nottingham Research Ethics Committee 1 ref. 09/H0407/1)
and the study was registered with the UK clinical research network (http://public.ukcrn.org.uk/search/ with
identifier number 7206). Informed written consent was obtained for all participants.
Study design
This was a prospective observational study of patients with CF undergoing standard intravenous treatment
for a pulmonary exacerbation, defined using the Rosenfeld criteria [8]. Both the antibiotic therapy
and the duration of treatment were chosen at the discretion of the patient’s clinician, and treatment
decisions were based on current clinical guidelines [9]. Spontaneous sputum, 8 mL blood and 25 mL urine
samples were obtained within 72 h of the start and end of i.v. antibiotic therapy. Pulmonary function tests
were performed according to standardised criteria [10] at the start and end of i.v. therapy. Comparable
paired samples were also collected at clinical stability for a subset of patients, either before or after the
exacerbation of interest, when the participant had not experienced a pulmonary exacerbation requiring i.v.
antibiotics in the previous 4 weeks. Patients were recruited only once into the study. CF related diabetes
mellitus was defined according to national guidelines [11]. Sputum or cough swabs were processed in the
hospital laboratory using standard microbiological techniques [12].
Sample analysis
Sputum plugs were harvested and processed for differential cell analysis [13], quantitative microbiology,
measurement of QSSMs [14, 15] and routine hospital microbiological culture [12]. Sputum plugs for
quantitative microbiological analysis were mixed with an equal volume of dithiothreitol and diluted with
0.9% weight/volume saline and 100 µL of ×10−2 and ×10−4 solutions were plated on blood and
Pseudomonas isolation agar (Difco; BD, Sparks, MD, USA). The plates were incubated at 37°C and colony
counts were performed daily between 24 h and 72 h, until maximal growth was achieved.
QSSM analysis
Sputum samples for QSSM analysis were extracted using acidified ethyl acetate (Fisher Chemicals,
Loughborough, UK) [14, 15]. Urine and plasma samples were extracted by solid phase extraction (further
details are provided in the online supplementary material). Prepared samples were then analysed by liquid
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chromatography-tandem mass spectrometry (LC-MS/MS), further details are provided in the online
supplementary material [14].
Statistics
Spearman’s rank correlations and Wilcoxon matched pairs signed-rank tests were used appropriately
(further details are provided in the online supplementary material).
Results
Study population
60 participants were enrolled (50 patients from Nottingham University Hospitals NHS Trust and 10 patients
from Heart of England NHS Foundation Trust) of which 34 (57%) were male. One participant died during
the hospital admission and data were only available for this patient at the start of the exacerbation.
Additional samples were collected from 29 participants at clinical stability, with eight samples taken before
the exacerbation of interest and 21 samples post exacerbation.
The i.v. therapy consisted of at least two antipseudomonal antibiotics, usually an aminoglycoside combined
with an antipseudomonal β-lactam (table 1) for a median (range) of 14 days (9–29 days). The median (IQR)
for the duration of pulmonary infection with P. aeruginosa was 7.6 years (3.7–12.5). 55 (92%) patients were
TABLE 1 Participants’ characteristics, sputum microbiology and antibiotics administered at
baseline
Demographics
Age years 29.3±10.4
Height m 1.68±0.09
Body mass index kg·m−2 21.9±3.7
Spirometry#
Absolute FEV1 L 1.70±0.70
FEV1 % pred 47.2±16.9
Absolute forced vital capacity L 2.79±1.03
Forced vital capacity % pred 65.4±19.2
Maintenance therapies
Nebulised colomycin 38 (63)
Nebulised tobramycin 6 (10)
Nebulised DNAse 36 (60)
Nebulised hypertonic saline 21 (35)
Oral corticosteroids 11 (18)
Oral azithromycin 49 (82)
Hospital microbiology results
Pseudomonas aeruginosa alone 42 (70)
Pseudomonas aeruginosa co-infection
MSSA 5 (8)
MRSA and Haemophilus influenzae 1 (2)
MRSA 1 (2)
Candida albicans 4 (7)
Pseudomonas aeruginosa not isolated
MRSA alone 2 (3)
MSSA alone 1 (2)
MSSA and Aspergillus fumigatus 1 (2)
Respiratory commensals only 3 (5)
Intravenous antibiotic administered
Tobramycin 32 (53)
Ceftazidime 29 (48)
Colomycin 24 (40)
Meropenem 24 (40)
Aztreonam 7 (12)
Piperacillin/tazobactam 5 (8)
Other¶ 5 (8)
Data are presented as mean±SD or n (%). FEV1: forced expiratory volume in 1 s; MSSA: methicillin-sensitive
Staphylococcus aureus; MRSA: methicillin-resistant S. aureus. #: n=58; ¶: other antibiotics consisted of
intravenous flucloxacillin (n=2), septrin (n=1), linezolid (n=1) and ofloxacillin (n=1).
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pancreatic exocrine insufficient, 33 (55%) patients had a diagnosis of CF related diabetes mellitus, 13 (22%)
patients had CF related liver disease, 8 (13%) patients had allergic bronchopulmonary aspergillosis and 2 (3%)
had asthma. 57 (95%) participants produced a sputum sample for hospital microbiological analysis and three
required a cough swab. P. aeruginosa was isolated from 53 (88%) samples, of which 42 (70%) samples had
P. aeruginosa only isolated from them and 11 (18%) samples had P. aeruginosa isolated in combination with
other microorganisms (table 1).
Individual QSSMs in sputum, plasma and urine were significantly correlated with each other at
the start of a pulmonary exacerbation
Cross-sectionally, at least one QSSM was detectable in the sputum, plasma and urine of 51 (86%), 42 (75%)
and 49 (83%), respectively, of patients who provided samples at the start of a pulmonary exacerbation. Eight
different QSSMs were detectable in sputum, six were detectable in plasma and four were detectable in urine
(table 2). 2-nonyl-3-hydroxy-4(1H )-quinolone (C9-PQS), was only detected in the plasma of one patient
and was not included in further analysis. Detection rates for QSSMs at the start of antibiotics in each
biofluid ranged from 8 (14%) for plasma 2-heptyl-3-hydroxy-4(1H )-quinolone (PQS) to 48 (81%)
for urinary 2-heptyl-4-hydroxyquinoline-N-oxide (HQNO) (table 2). Of the 53 patients with positive
P. aeruginosa culture from the hospital laboratory at baseline, QSSMs were detectable in the sputum,
plasma and urine of 47 (89%), 39 (78%) and 44 (85%) samples respectively. Of the seven patients whose
sputum did not isolate P. aeruginosa in the hospital laboratory at baseline, QSSMs were detected in all three
biofluids from two patients, in the sputum and urine from two patients, in the urine and plasma of one
patient and none were detected in any of the biofluids tested from two patients (table S1). Subsequent
hospital laboratory sputum cultures isolated P. aeruginosa in all seven cases with a median (IQR) of
4.0 months (1.5–6.9 months) post hospitalisation. There were no significant associations observed between
prior maintenance usage of azithromycin and QSSM levels in any of the biofluids.
2-heptyl-4-hydroxyquinoline (HHQ), 2-nonyl-4-hydroxyquinoline (NHQ), HQNO and 2-nonyl-4-
hydroxyquinoline-N-oxide (NQNO) had clearly identifiable peaks in all three body fluids allowing
TABLE 2 Quorum sensing molecule signal concentrations in sputum, plasma and urine before and after administration of
intravenous antibiotics for a pulmonary exacerbation in cystic fibrosis patients
Pre-antibiotics Post antibiotics p-value#
Signal
detectable Signal concentration
Signal
detectable Signal concentration
pmol·mL−1 pmol·L−1 pmol·mL−1 pmol·L−1
Sputum¶
HHQ 35 (59) 14 (LLOQ–1066) 31 (57) 24 (LLOQ–130 000) 0.18
NHQ 43 (73) 13 (LLOQ–1563) 33 (61) 22 (LLOQ–220 000) 0.17
HQNO 47 (80) 4 (LLOQ–780) 35 (65) 2 (LLOQ–710) 0.80
NQNO 26 (44) LLOQ (LLOQ–1075) 17 (31) LLOQ (LLOQ–1011) 0.52
C7-PQS 21 (36) LLOQ (LLOQ–873) 12 (22) LLOQ (LLOQ-673) 0.30
C9-PQS 16 (27) LLOQ (LLOQ–4302) 11 (20) LLOQ (LLOQ–8170) 0.91
3-oxo-C12-HSL 38 (64) 4 (LLOQ–410) 34 (63) 4 (LLOQ–2614) 0.69
C4-HSL 18 (31) LLOQ (LLOQ–145) 14 (26) LLOQ (LLOQ–192) 0.62
Plasma+
HHQ 40 (71) 117 (LLOQ–2744) 33 (59) 86 (LLOQ–2014) 0.02
NHQ 25 (45) LLOQ (LLOQ–222) 15 (27) LLOQ (LLOQ–160) 0.004
HQNO 21 (38) LLOQ (LLOQ–904) 16 (29) LLOQ (LLOQ–898) 0.96
NQNO 15 (27) LLOQ (LLOQ–705) 12 (21) LLOQ (LLOQ–453) 0.87
C7-PQS 8 (14) LLOQ (LLOQ–571) 5 (9) LLOQ (LLOQ–455) 0.06
Urine§
HHQ 31 (53) 95 (LLOQ–4028) 32 (54) 102 (LLOQ–8936) 0.65
NHQ 19 (32) LLOQ (LLOQ–347) 18 (31) LLOQ (LLOQ–501) 0.69
HQNO 48 (81) 311 (LLOQ–12 511) 40 (68) 113 (LLOQ–13 576) 0.74
NQNO 16 (27) LLOQ (LLOQ–2067) 12 (20) LLOQ (LLOQ–2625) 0.76
Data presented as n (%) or median (range), unless otherwise state. HHQ: 2-heptyl-4-hydroxyquinoline; NHQ: 2-nonyl-4-hydroxyquinoline;
HQNO: 2-heptyl-4-hydroxyquinoline-N-oxide; NQNO: 2-nonyl-4-hydroxyquinoline-N-oxide; C7-PQS: 2-heptyl-3-hydroxy-4(1H )-quinolone;
C9-PQS: 2-nonyl-3-hydroxy-4(1H )-quinolone; 3-oxo-C12-HSL: N-(3-oxododecanoyl)-L-homoserine lactone; C4-HSL: N-butanoyl-L-homoserine
lactone; LLOQ: lower limit of quantification (see online supplement for further details). #: Wilcoxon matched pairs signed-rank sum test;
¶: n=59 for pre-antibiotics and n=54 for post antibiotics; +: n=56 for pre-antibiotics and n=56 for post antibiotics; §: n=59 for pre-antibiotics and
n=59 for post antibiotics, where n=number of patients with samples available for analysis.
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comparisons between the levels of these molecules in different biofluids. At the start of the pulmonary
exacerbation, sputum, plasma and urinary levels of HHQ, NHQ and HQNO were positively correlated with
each other in all three biofluids (table 3). Overall, the strongest relationships were found for HHQ, with the
sputum signal positively correlated with both plasma (r=0.72, p<0.0001) and urinary concentrations
(r=0.63, p<0.0001). For all four molecules, plasma levels were significantly correlated with both sputum
(p<0.001 for all comparisons) and urinary levels (p=0.02 to <0.001).
QSSMs were positively associated with higher quantitative load of P. aeruginosa at the start of a
pulmonary exacerbation
A higher P. aeruginosa load, at the start of antibiotic treatment, was associated with increased signal
concentration in six of the eight QSSMs detected in sputum (table 4) with the highest correlation
demonstrated with N-butanoyl-L-homoserine lactone (r=0.53, p<0.0001). At the start of antibiotic treatment,
all plasma QSSMs were associated with P. aeruginosa density; the strongest relationship between bacterial
TABLE 3 Cross-sectional association between baseline sputum, plasma and urinary signal
concentrations for the four alkyl quinolones detected in all three media
QSSM Sputum and plasma# Sputum and urine¶ Plasma and urine+
HHQ 0.72 (<0.0001) 0.63 (<0.0001) 0.80 (<0.0001)
NHQ 0.49 (0.0002) 0.65 (<0.0001) 0.54 (<0.0001)
HQNO 0.56 (<0.0001) 0.61 (<0.0001) 0.63 (<0.0001)
NQNO 0.58 (<0.0001) 0.13 (0.34) 0.32 (0.02)
Data are presented as Spearman’s correlation coefficient (p-value). QSSM: quorum sensing signal molecule;
HHQ: 2-heptyl-4-hydroxyquinoline; NHQ: 2-nonyl-4-hydroxyquinoline; HQNO: 2-heptyl-4-hydroxyquinoline-N-oxide;
NQNO: 2-nonyl-4-hydroxyquinoline-N-oxide. #: n=55; ¶: n=58; +: n=56, where n is number of participants with
samples available for analysis.
TABLE 4 Cross-sectional association between the bacterial cell density of Pseudomonas
aeruginosa and quorum sensing signal molecule (QSSM) concentration in sputum, plasma and
urine
QSSM Spearman’s correlation coefficient p-value
Sputum#
HHQ 0.52 0.0001
NHQ 0.50 0.0001
HQNO 0.35 <0.01
NQNO 0.34 0.01
C7-PQS 0.43 0.001
C9-PQS 0.27 <0.05
3-oxo-C12-HSL 0.27 <0.05
C4-HSL 0.54 <0.0001
Plasma¶
HHQ 0.51 <0.001
NHQ 0.30 0.03
HQNO 0.49 <0.001
NQNO 0.35 0.01
C7-PQS 0.37 <0.01
Urine+
HHQ 0.30 0.03
NHQ 0.29 0.03
HQNO 0.32 0.02
NQNO 0.36 <0.01
Median (interquartile range) for sputum bacterial load of Pseudomonas aeruginosa was 9.6×106 CFU·g−1
(1.3×106–5.7×107 CFU·g−1). HHQ: 2-heptyl-4-hydroxyquinoline; NHQ: 2-nonyl-4-hydroxyquinoline; HQNO: 2-heptyl-
4-hydroxyquinoline-N-oxide; NQNO: 2-nonyl-4-hydroxyquinoline-N-oxide; C7-PQS: 2-heptyl-3-hydroxy-4(1H )-quinolone;
C7-PQS: 2-nonyl-3-hydroxy-4(1H )-quinolone; 3-oxo-C12-HSL: N-(3-oxododecanoyl)-L-homoserine lactone;
C4-HSL: N-butanoyl-L-homoserine lactone. #: n=54; ¶: n=50; +: n=53, where n is the number of patients
with samples available for analysis.
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load and QSSM was demonstrated for HHQ (r=0.51, p<0.001). Similarly, at the start of antibiotic treatment
all urine levels of QSSMs were also associated with quantitative measures of P. aeruginosa load; the strongest
association observed was for NQNO (r=0.36, p<0.01). Significantly positive associations were found between
per cent predicted forced expiratory volume in 1 s (FEV1) and sputum HHQ (r=0.31, p=0.02) (fig. S1) and
NHQ (r=0.30, p=0.02) (fig. S2), but not with other QSSMs in any media. No significant associations were
found between sputum neutrophil concentrations and QSSM levels (data not shown).
Longitudinal analysis at start and end of exacerbation: plasma HHQ and NHQ concentrations fell
significantly after i.v. antibiotics
Following the administration of antibiotics, plasma concentrations of HHQ and NHQ decreased significantly
(table 2). For HHQ, the number of samples with detectable signal fell from 40 (71%) to 33 (59%) after the
administration of antibiotics (p=0.02) and the comparable figures for NHQ were a decrease from 25 (45%)
samples with detectable signal to 15 (27%) positive samples (p=0.004). However, corresponding sputum and
urinary signals did not change significantly for either QSSM (table 2). No changes in QSSM signal
concentration were demonstrated for the remaining QSSMs detected in sputum, plasma or urine following
treatment with antibiotics (table 2). Over the same period, mean (95% CI) increase in FEV1 was 253 mL
(179–326 mL) or 6.1% pred (4.0–8.1% pred) and the increase in FVC was 269 mL (145–393 mL) or 6.3%
pred (3.3–9.2% pred). Mean sputum neutrophil concentration decreased from 7.1 to 6.9 log cells·g−1
(p<0.001) following antibiotic therapy, but no change in quantitative microbiological load was demonstrated
using blood (p=0.22) (table S2) or pseudomonas isolation agar (p=0.98) (table S2).
Longitudinal analysis from the start of the exacerbation compared with clinical stability: plasma
NHQ increased at presentation with exacerbation
Data were available from 29 individuals who provided paired data at the beginning of the clinical
exacerbation and also during a period of clinical stability. Compared to the period of clinical stability,
plasma NHQ was increased at presentation for treatment at the beginning of an exacerbation (p=0.008)
(fig. 1), while sputum NQNO, sputum C7-PQS and plasma NQNO were lower at this time (p=0.009,
p=0.03 and p=0.003, respectively). There was no difference in quantitative microbiological load of
P. aeruginosa measured at clinical stability when compared with the start of the pulmonary exacerbation
(median values of 1.2×107 CFU·g−1 and 1.0×107 CFU·g−1 of sputum, respectively).
Discussion
This is the first study to test the hypothesis that QSSMs may be correlated with clinical status in the
context of a pulmonary exacerbation in adults with CF and chronic pulmonary P. aeruginosa. We have
observed for the first time that a number of different QSSMs are detectable in sputum, plasma and urine
in this patient group at the start of a pulmonary exacerbation. In particular, one QSSM (NHQ) in the
plasma was elevated at the start of a pulmonary exacerbation, when compared to the baseline, and
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FIGURE 1 Plasma concentrations of 2-nonyl-4-hydroxy-quinoline (NHQ) in 29 patients with cystic fibrosis at
clinical stability (eight samples before the exacerbation and 21 samples after the exacerbation of interest)
compared to the beginning of a pulmonary exacerbation.
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decreased significantly after treatment, suggesting this molecule may be sensitive to changes in clinical
status and has particular potential as a biomarker in this setting.
The strengths of this study include the prospective study design and testing of predetermined hypotheses.
The cohort was well characterised with a broad range in lung disease severity, suggesting our findings may
be applicable to wider populations with similar severity of respiratory disease, but not necessarily those
with mild or end-stage disease. The samples were collected following a rigorous protocol and processed in
line with conventional practice, thereby reducing any variance in the signals generated by random error.
We excluded patients that had previously isolated other respiratory pathogens capable of producing alkyl
quinolones, such as Burkholderia cepacia complex [16], used hospital microbiological culture to validate
our findings, and quantitative microbiological measures of P. aeruginosa to allow more detailed statistical
assessment of the associations of interest. This had the added advantage of allowing comparison of the
new candidate biomarkers alongside conventional practice, demonstrating that a positive QSSM signal was
present even when the conventional microbiological culture was negative for P. aeruginosa. The availability
of measures of lung function and quantitative markers of pulmonary inflammation objectively confirmed
the observed clinical recovery of the individual patients. Additional paired data from a period of clinical
stability allowed more detailed longitudinal comparisons of QSSM concentrations with clinical status for
approximately half of the participants.
Our study has some limitations that need consideration. The study design required the measurement of
eight QSSMs using a targeted and quantitative LC-MS/MS method. This was a necessary requirement of
this study design to permit the identification of the QSSMs, which have the greatest potential as
biomarkers, and the testing of multiple hypotheses requires consideration when interpreting these data.
The large number of negative values that we observed for all biofluids in patients known to be infected
with P. aeruginosa raises the possibility that QSSMs are present but below the lower limit of quantification
(LLOQ) (for further details refer to the online supplementary material) for detection by the LC-MS/MS
method. Alternatively, the concurrent use of azithromycin in the majority of CF patients in this study may
have resulted in a reduction in QSSM concentrations [17], or some populations of P. aeruginosa may have
evolved with reduced or absent ability to produce QSSMs [18]. The collection of urine samples was not
standardised and used a random “catch”, which would be expected to increase the random error of any
molecules measured as the concentration may vary. Future studies assessing the potential of urinary
QSSMs as biomarkers should consider correcting for urinary creatinine concentration to allow for
differential dilution. Future studies may also consider comparisons between QSSM levels and systemic
biomarkers of inflammation, such as C reactive protein. Finally, we were unable to generate detailed
phenotypes for the bacterial population isolated from the clinical samples due to resource constraints, and
this is an option for future studies in this cohort.
There are several observations in our data that require further consideration. Firstly, the QSSMs that
changed over the course of antibiotic treatment were found to decline in the plasma but not in the sputum
samples collected. All samples were collected and analysed in the same rigorous manner and we doubt
that this is an artefact and consider that it is likely to be a true negative. It is possible that concentrations
of QSSMs in plasma may reflect the total QSSM load in the host more accurately than sputum samples
from the lungs, which are susceptible to sampling variation as a consequence of the heterogeneous nature
of infection with P. aeruginosa in the CF airways [19]. Differences in local environmental conditions
within the lung, such as nutrient availability, may influence QSSM production [20] and may contribute to
the relatively poor correlations between QSSM levels and the quantity of P. aeruginosa observed in this
study and by others [21]. Alternatively, the clearance of QSSMs may differ between sputum and plasma
and an interval of greater than a median of 14 days may be required to detect changes in these measures
in the lung. QSSMs in the blood may be excreted or metabolised faster than those in the lung and, thus,
would be expected to have a shorter half-life, a hypothesis that is consistent with our data. This has
important implications for future studies that aim to monitor sputum and plasma QSSMs over time. The
second observation that requires consideration is that some QSSMs were positively correlated with FEV1 in
cross-sectional analysis at the start of a pulmonary exacerbation and the reasons for this unexpected
finding are not known. One possible explanation is that patients with lower lung function are likely
to have had a higher cumulative exposure to antibiotics that could potentially reduce QSSM production by
P. aeruginosa [22, 23]. Alternatively, patients with lower lung function may have a longer duration of
infection with P. aeruginosa and this may be associated with a reduction in QSSM levels as a result of
cumulative mutations in the QS regulatory genes over time [24, 25].
Overall, our data suggest that clinical status may be associated with changes in systemic QSSMs, rather than
absolute changes in bacterial numbers, and that i.v. antibiotics may lead to a reduction in systemic QSSMs in
the context of a pulmonary exacerbation. One potential explanation for this observation is that some of the
therapeutic effect of systemic antibiotics may be mediated via QSSMs. This hypothesis is consistent with studies
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that have shown that bacterial load is poorly correlated with clinical status [26, 27], that the CF microbiome is
relatively resistant to antibiotics [28] and that several classes of antibiotics routinely used in the management of
patients with CF may inhibit QSSM or QS-mediated virulence factor production [22, 23, 29, 30].
The implications of these data are that QSSMs have the potential to provide biomarkers for P. aeruginosa
and this may lead to the possibility of non-pulmonary measures of infection using plasma or urinary samples.
In particular, plasma biomarkers that are sensitive to i.v. antibiotics and subsequent clinical improvement
may provide a new tool to assess response to treatment in future. We observed consistent signals in molecules
from the alkyl quinolone category, which is compatible with the hypothesis that they have the greatest
potential as novel biomarkers for P. aeruginosa as they are only produced by this bacterium and a few closely
related species and P. aeruginosa is the only species known to produce PQS [16]. This study represents an
early stage in the investigation of QSSMs as novel biomarkers for P. aeruginosa and to bring this test to
routine clinical practice would require further validation steps and the development of simple point of care
assay, similar to those used in diabetic control monitoring. These data also suggest that investigation into the
potential use of QSSMs as biomarkers for the early detection of P. aeruginosa should be explored, given the
current limitations of diagnosing lower respiratory tract infections in those unable to expectorate sputum. In
future, this test may have wider clinical applications in other diseases in which P. aeruginosa is an important
pathogen, such as non-CF bronchiectasis [31] and chronic obstructive pulmonary disease [32].
In conclusion, we report for the first time that QSSMs are detectable in sputum, plasma and urine in
patients with a pulmonary exacerbation of CF. In particular, plasma NHQ is increased at the presentation
with an exacerbation compared to clinical stability, and decreases after administration of i.v. antibiotics,
suggesting this molecule may be sensitive to clinical changes and has potential as a biomarker to assess
response to treatment in future.
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